Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168361 | 0.96 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21168306 | 0.96 | KMT2A (0.36) | FOLH1KMT2AVSIRCD274NAALAD2 | |
| SCHEMBL21168304 | 0.93 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21168324 | 0.92 | FOLH1 (0.44) | FOLH1VSIRCD274C3AR1 | |
| SCHEMBL21999116 | 0.92 | VSIR (0.36) | FOLH1KMT2AVSIRCD274NAALAD2 | |
| SCHEMBL24058479 | 0.91 | VSIR (0.43) | FOLH1KMT2AVSIRCD274NAALAD2 | |
| SCHEMBL24058887 | 0.91 | VSIR (0.39) | FOLH1KMT2AVSIRCD274NAALAD2 | |
| SCHEMBL25477024 | 0.91 | VSIR (0.35) | FOLH1KMT2AVSIRCD274NAALAD2 | |
| SCHEMBL21168314 | 0.90 | FOLH1 (0.44) | FOLH1VSIRCD274C3AR1 | |
| SCHEMBL19969099 | 0.89 | VSIR (0.39) | FOLH1KMT2AVSIRCD274CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | FOLH1 3156/4885KMT2A 2453/4885VSIR 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.